Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report sent to investors on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Roth Mkm reiterated a buy rating and set a $40.00 target price on shares of Bio-Path in a report on Thursday, April 18th.

Bio-Path Stock Performance

Shares of NASDAQ:BPTH opened at $2.68 on Wednesday. The company has a market cap of $1.82 million, a P/E ratio of -0.07 and a beta of 0.35. Bio-Path has a one year low of $2.35 and a one year high of $44.80. The business’s 50-day simple moving average is $4.77 and its 200 day simple moving average is $8.36.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, meeting the consensus estimate of ($5.40). During the same period in the previous year, the company earned ($10.60) EPS. Analysts predict that Bio-Path will post -18.71 earnings per share for the current year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.